Robotic RPLND for stage IIA/B nonseminoma: the Princess Margaret Experience

Area of Science:

• Urology
• Surgical Oncology
• Minimally Invasive Surgery

Background:

• Retroperitoneal lymph node dissection (RPLND) is a key treatment for non-seminoma germ cell tumors (NSGCT).
• Robotic-assisted surgery offers potential advantages in complex procedures.

Purpose of the Study:

• To review the feasibility, safety, and outcomes of robotic RPLND for clinical stage I/II NSGCT.
• To highlight the adoption and experience with robotic RPLND at Princess Margaret.

Main Methods:

• Systematic review of published data on robotic RPLND for stage IIA/B non-seminoma.
• Analysis of institutional data from Princess Margaret.

Main Results:

• Robotic RPLND is feasible and safe in experienced centers, with promising reductions in blood loss, hospital stay, and morbidity.
• Institutional data showed oncologic efficacy, with an 11% relapse rate comparable to open RPLND in patients not receiving adjuvant chemotherapy.

Conclusions:

• Robotic RPLND demonstrates comparable oncologic outcomes to open surgery.
• It should be performed in experienced centers by high-volume surgeons within a protocol setting until established as the gold standard.